XML 44 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Agreements (Details) - USD ($)
 1 Months Ended 2 Months Ended 12 Months Ended
May 06, 2016
Jul. 24, 2017
May 26, 2017
Feb. 28, 2017
Mar. 31, 2016
Sep. 30, 2015
Sep. 30, 2017
Sep. 30, 2016
Jun. 01, 2017
Aug. 26, 2016
Dec. 29, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Amount received from BriVision             $ 4,113,000 $ 6,500,000      
Common stock newly issued, value           $ 51,958 5,850,000 3,250,000      
Research and development expense             $ 3,151,162 $ 10,000,000      
Collaborative Arrangement [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Description of payment settlement schedule            
  ● upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.
     
  ● upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.
     

  ● at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.
     
  ● upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.
     
  ● at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.
     
  ● upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week. 

        
Amount received from BriVision   $ 3,000,000                 $ 100,000,000
Upfront payments             $ 3,500,000        
Percentage of payments under collaborative agreement   50.00%   15.00%     3.50%        
Milestone payments to BioLite in cash $ 2,600,000                    
Common stock newly issued, value $ 900,000 $ 3,000,000                  
Common stock newly issued, shares 562,500                    
Share price $ 1.60     $ 2.0              
Licensing rights             $ 10,000,000        
Accounts payable       $ 15,000,000              
Co-Dev Agreement [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Amount received from BriVision     $ 3,000,000           $ 450,000    
Percentage of payments under collaborative agreement     50.00%                
Common stock newly issued, value             3,000,000        
Company cash payments     $ 3,000,000                
Collaborative Arrangement One [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Amount received from BriVision                   $ 100,000,000  
Percentage of payments under collaborative agreement         6.50%            
Milestone payments to BioLite in cash       650,000              
Common stock newly issued, value       $ 5,850,000              
Common stock newly issued, shares       2,925,000              
Share price       $ 2.0              
Licensing rights             3,000,000        
Accounts payable         $ 6,500,000            
Research and development expense             $ 3,000,000